Palliser Capital (UK)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Palliser Capital (UK)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.21M	Buy	+27,954	New	+$7.93M	4.41%	4

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Palliser Capital (UK)'s BIO Position: Q2 2026 in Review

Palliser Capital (UK) opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 27,954 shares worth $8.21M. The stake represents 4.41% of the portfolio and ranks #4 among its holdings.

397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Palliser Capital (UK) held 27,954 shares of Bio-Rad Laboratories Class A worth $8.21M as of Q2 2026.
Bio-Rad Laboratories Class A was a new Palliser Capital (UK) position in Q2 2026.
Bio-Rad Laboratories Class A made up 4.41% of Palliser Capital (UK)'s portfolio in Q2 2026, its #4 holding.
397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Palliser Capital (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.